High-dose cyclophosphamide, without stem cell rescue, has been used successfully to treat aplastic anemia and other autoimmune disorders. To determine the safety and efficacy of high-dose cyclophosphamide among patients with severe refractory autoimmune hemolytic anemia, we treated 9 patients with cyclophosphamide (50 mg  ·  kg−1  ·  d−1 for 4 days) who had failed a median of 3 (range, 1-7) other treatments. The median hemoglobin before treatment was 6.7 g/dL (range, 5-10 g/dL). The median time to reach an absolute neutrophil count of 500/μL or greater was 16 days (range, 12-18 days). Six patients achieved complete remission (normal untransfused hemoglobin for age and sex), and none have relapsed after a median follow-up of 15 months (range, 4-29 months). Three patients achieved and continue in partial remission (hemoglobin at least 10 g/dL without transfusion support). High-dose cyclophosphamide was well tolerated and induced durable remissions in patients with severe refractory autoimmune hemolytic anemia.

High-dose cyclophosphamide was initially chosen as conditioning for allogeneic bone marrow transplantation because of its potent immunosuppressive properties.1,2Lymphocytes are highly sensitive to cyclophosphamide, but primitive hematopoietic progenitors are resistant to its cytotoxic effects because they contain high levels of aldehyde dehydrogenase, an enzyme that confers resistance to cyclophosphamide.3 We and others showed that high-dose cyclophosphamide without stem cell transplantation induces durable treatment-free remissions in patients with severe aplastic anemia.4-6 This approach also has activity in a variety of other refractory autoimmune conditions7-9 and can eliminate alloantibodies.10 Moreover, it avoids the risk of reinfusing autoreactive effector cells with the autograft during stem cell transplantation, a potential source of relapse.

Autoimmune hemolytic anemia (AIHA) has a prevalence of 1 per 100 000 and may be life-threatening.11 The disease is classified as primary (idiopathic) or secondary if there is an underlying disorder. The associated antibody that causes hemolysis is either a warm antibody or a cold agglutinin.11 Treatment with glucocorticoids results in improvement in the majority of cases, but relapse is common.12 For patients whose disease becomes refractory or who do not respond to glucocorticoids, splenectomy is often employed as a second-line treatment.12 Subsequent salvage treatments include intravenous immunoglobulin, danazol,13 and a variety of immunomodulating agents including low-dose cyclophosphamide, azathioprine, cyclosporine, and vincristine.12 Unfortunately, many patients become refractory to multiple therapeutic approaches and develop complications of chronic high-dose steroid therapy. Cold agglutinin autoimmune hemolytic anemia is particularly refractory to treatment. Because of its success in other severe autoimmune disorders, high-dose cyclophosphamide was studied in patients with severe AIHA that was refractory to standard therapies.

All patients gave informed consent for study participation as approved by the institutional review boards at Johns Hopkins Hospital and Johns Hopkins University (JHH) and at Medical College of Pennsylvania, Hahnemann University (MCPH). Between November 1998 and June 2001, 9 patients (JHH 6; MCPH 3) with severe refractory AIHA were treated with high-dose cyclophosphamide (50 mg/kg ideal body weight per day) intravenously for 4 consecutive days. Mesna (sodium 2-mercaptoethanesulfonate) 10 mg/kg was given at 3, 6, and 8 hours following each cyclophosphamide dose. Granulocyte colony-stimulating factor at 5 μg/kg was initiated 6 days after the completion of treatment with high-dose cyclophosphamide and continued until an absolute neutrophil count (ANC) of 1000/μL or greater was attained. Patients had to be 70 years of age or younger and were required to have severe AIHA that had failed standard therapy (at least 2 standard therapies for primary AIHA and at least 1 standard therapy for secondary AIHA). Patients were also required to be steroid dependent by the criterion of inability to taper the prednisone dose to less than 10 mg/d. Other inclusion criteria were cardiac ejection fraction greater than 40%, serum creatinine value less than 2.5 mg/dL, and pulmonary function tests showing forced vital capacity, forced expiratory volume, and carbon monoxide diffusion in the lung at least 50% of predicted values.

A diagnosis of AIHA was made on the basis of severe anemia, a positive direct antiglobulin test (DAT for IgG and C3b), or the presence of cold agglutinin in the serum, and corroborating evidence of hemolysis (unconjugated hyperbilirubinemia, elevated lactate dehydrogenase, low serum haptoglobulin levels). Following treatment with high-dose cyclophosphamide, patients were provided with supportive care as described previously.5 A complete remission (CR) was defined as achieving a normal untransfused hemoglobin for age and sex while taking less than or equal to 10 mg/d prednisone and the resolution of hemolysis; partial response (PR) was defined as achieving a hemoglobin of 10 g/dL or greater following treatment and transfusion independence.12 14 

The patient characteristics and response to treatment are shown in Table 1. There were 5 males and 4 females with a median age of 52 years (range, 7-64 years). Of the 9 patients, 7 had the warm-antibody variety of hemolytic anemia, 1 patient had a combination of both warm and cold antibodies, and 1 patient had purely cold-agglutinin disease. Six patients had primary AIHA and 3 patients had secondary AIHA. The underlying diseases in patients with secondary AIHA included chronic lymphocytic leukemia, Castleman disease, and graft-versus-host disease following allogeneic transplantation. The patients had received a median of 3 (range, 1-7) treatment modalities; splenectomy was performed in 3 patients. The median hemoglobin at the time of treatment was 6.7 g/dL (range, 5-10 g/dL), and 8 patients were erythrocyte transfusion dependent.

Table 1.

Patient characteristics and response to high-dose cyclophosphamide

Patient no.Age; sexAntibody type (disease duration)Associated diseasePrior therapyPretreatment statusStatus at dischargeCurrent statusMonths of follow-up
56; F Warm DAT (+); cold agg. (+)
(9 y) 
None Glucocorticoids, splenectomy, oral cyclophosphamide, cyclosporine HB 5 g/dL*; DAT (+); cold agg (+); no therapy HB 9.9 g/dL; DAT (+); cold agg (+) PR HB 11.1 g/dL; DAT (+); cold agg (+); off therapy 29  
52; M Warm DAT (+)
(4 mo) 
None Glucocorticoids, splenectomy, azathioprine, hydroxychloroquine, ascorbic acid, intravenous immunoglobulin HB 6 g/dL; DAT (+); prednisone 30 mg HB 9.0 g/dL; DAT (+); prednisone 30 mg CR HB 13.7 g/dL; DAT (−); off therapy 16  
55; F Warm DAT (+) (18 mo) None Glucocorticoids, cyclosporine, intravenous immunoglobulin HB 6.8 g/dL; DAT (+); prednisone 40 mg HB 9.0 g/dL; DAT (+); prednisone 40 mg CR HB 14.7 g/dL; DAT (−); off therapy 15  
64; M Cold agg (+)
(40 mo) 
None Glucocorticoids, chlorambucil HB 10 g/dL; cold agg (+); prednisone 40 mg HB 9.0 g/dL; cold agg (+); prednisone 40 mg CR HB 15 g/dL; cold agg (+); off therapy 16  
39; M Warm DAT (+) (12 mo) None Glucocorticoids, intravenous immunoglobulin, oral cyclophosphamide HB 5 g/dL; DAT (+); prednisone 60 mg HB 9.6 g/dL; DAT (+); prednisone 40 mg CR HB 14 g/dL; DAT (+); off therapy 18  
7; M Warm DAT (+) (46 mo) GVHD following allogeneic BMT at age 2 y for Hurler syndrome Glucocorticoids, azathioprine, mycophenolate mofetil, FK 506, intravenous immunoglobulin HB 6.5 g/dL; DAT (+); prednisolone 35 mg, FK 506 (3 mg) HB 7.1 g/dL; DAT (+); prednisolone 35 mg, FK 506 (0.4 mg) PR HB 13.8 g/dL; DAT (+); dexamethasone 1.75 mg; QOD rituximab 15  
45; F Warm DAT (+) (23 mo) Castleman disease Glucocorticoids, rituximab HB 6.5 g/dL; DAT (+); no therapy HB 10.4 g/dL; DAT (+); no steroids PR HB 14 g/dL; DAT (+); rituximab 15  
55; M Warm DAT (+)
(3 mo) 
Chronic lymphocytic leukemia Glucocorticoids HB 6.9 g/dL; DAT (+); prednisone 50 mg HB 14.3 g/dL; DAT (+); prednisone 20 mg CR HB 14.9 g/dL; DAT (+); off therapy 11  
48; F Warm DAT (+) (on and off 30 y) None Glucocorticoids, splenectomy, vincristine, intravenous immunoglobulin, danazol, plasmapheresis, ascorbic acid HB 6.7 g/dL; DAT (+); prednisone 60 mg HB 8.4 g/dL; DAT (+); prednisone 40 mg CR HB 13.7 g/dL; DAT (+); prednisone 5 mg QOD 
Patient no.Age; sexAntibody type (disease duration)Associated diseasePrior therapyPretreatment statusStatus at dischargeCurrent statusMonths of follow-up
56; F Warm DAT (+); cold agg. (+)
(9 y) 
None Glucocorticoids, splenectomy, oral cyclophosphamide, cyclosporine HB 5 g/dL*; DAT (+); cold agg (+); no therapy HB 9.9 g/dL; DAT (+); cold agg (+) PR HB 11.1 g/dL; DAT (+); cold agg (+); off therapy 29  
52; M Warm DAT (+)
(4 mo) 
None Glucocorticoids, splenectomy, azathioprine, hydroxychloroquine, ascorbic acid, intravenous immunoglobulin HB 6 g/dL; DAT (+); prednisone 30 mg HB 9.0 g/dL; DAT (+); prednisone 30 mg CR HB 13.7 g/dL; DAT (−); off therapy 16  
55; F Warm DAT (+) (18 mo) None Glucocorticoids, cyclosporine, intravenous immunoglobulin HB 6.8 g/dL; DAT (+); prednisone 40 mg HB 9.0 g/dL; DAT (+); prednisone 40 mg CR HB 14.7 g/dL; DAT (−); off therapy 15  
64; M Cold agg (+)
(40 mo) 
None Glucocorticoids, chlorambucil HB 10 g/dL; cold agg (+); prednisone 40 mg HB 9.0 g/dL; cold agg (+); prednisone 40 mg CR HB 15 g/dL; cold agg (+); off therapy 16  
39; M Warm DAT (+) (12 mo) None Glucocorticoids, intravenous immunoglobulin, oral cyclophosphamide HB 5 g/dL; DAT (+); prednisone 60 mg HB 9.6 g/dL; DAT (+); prednisone 40 mg CR HB 14 g/dL; DAT (+); off therapy 18  
7; M Warm DAT (+) (46 mo) GVHD following allogeneic BMT at age 2 y for Hurler syndrome Glucocorticoids, azathioprine, mycophenolate mofetil, FK 506, intravenous immunoglobulin HB 6.5 g/dL; DAT (+); prednisolone 35 mg, FK 506 (3 mg) HB 7.1 g/dL; DAT (+); prednisolone 35 mg, FK 506 (0.4 mg) PR HB 13.8 g/dL; DAT (+); dexamethasone 1.75 mg; QOD rituximab 15  
45; F Warm DAT (+) (23 mo) Castleman disease Glucocorticoids, rituximab HB 6.5 g/dL; DAT (+); no therapy HB 10.4 g/dL; DAT (+); no steroids PR HB 14 g/dL; DAT (+); rituximab 15  
55; M Warm DAT (+)
(3 mo) 
Chronic lymphocytic leukemia Glucocorticoids HB 6.9 g/dL; DAT (+); prednisone 50 mg HB 14.3 g/dL; DAT (+); prednisone 20 mg CR HB 14.9 g/dL; DAT (+); off therapy 11  
48; F Warm DAT (+) (on and off 30 y) None Glucocorticoids, splenectomy, vincristine, intravenous immunoglobulin, danazol, plasmapheresis, ascorbic acid HB 6.7 g/dL; DAT (+); prednisone 60 mg HB 8.4 g/dL; DAT (+); prednisone 40 mg CR HB 13.7 g/dL; DAT (+); prednisone 5 mg QOD 

DAT indicates direct antiglobulin (Coombs) test; cold agg, cold-agglutinin screen; HB, hemoglobin in g/dL; PR, partial response; CR, complete response; GVHD, graft-versus-host disease; and BMT, bone marrow transplantation.

*

g/dL represents the hemoglobin with packed red blood cell transfusion; all other hemoglobin values represent nontransfused values.

QOD indicates every other day; prednisone doses reflect daily dosage unless stated otherwise.

High-dose cyclophosphamide was well tolerated. Common side effects included nausea, vomiting, transient alopecia, and neutropenic fever. There were no deaths or documented fungal infections, although one patient was treated empirically with amphotericin B for persistent neutropenic fever. The median number of hospital days was 21 (range, 15-25 days); however, 4 of the patients were hospitalized for complications of their AIHA before treatment with high-dose cyclophosphamide. The median times to an ANC of 500/μL or greater and to platelet-transfusion independence were 16 days (range, 12-18 days) and 15 days (range, 0-27 days), respectively. Patients became independent of packed red blood cell transfusion after a median of 19 days (range, 15-31 days) following treatment.

All patients became transfusion independent in response to treatment. Six patients went into CR, including 5 of 6 patients with primary AIHA, and 1 patient with secondary AIHA. The remaining 3 patients achieved a partial remission, including patient no. 1, who had both cold and warm antibodies and in whom the warm antibody was eliminated. The DAT became negative in 2 of the patients who achieved a CR. At the time of treatment, patients required a median of 40 mg/d (range, 0-60 mg/d) of prednisone. At last follow-up, only one of the patients in CR (patient no. 9) was receiving tapering doses of prednisone (5 mg every other day) and one other patient in PR (patient no. 6) was still taking dexamethasone at a low maintenance dose. All others had discontinued steroids. None of the patients had experienced relapse at a median follow-up of 15 months (range, 4-29 months).

For patients with AIHA in whom glucocorticoid treatment fails, splenectomy is frequently offered as second-line treatment.12,15 However, this approach is limited because splenectomy is generally ineffective for cold-agglutinin disease12 and may be less effective and have a higher complication rate in secondary AIHA.16,17 Of the 6 patients with primary AIHA, 3 had splenectomy, 2 refused the procedure, and 1 patient with cold-agglutinin disease was not offered the procedure. Splenectomy was not performed in any of the patients with secondary AIHA. There is little consensus on how to manage AIHA when corticosteroid therapy fails and when splenectomy is ineffective or is not an option.12 Treatments for these patients include low-dose cytotoxic therapy,12,15 danazol,13and intravenous immunoglobulin.18 Most of these treatments are only partially successful, with many patients becoming dependent on glucocorticoid maintenance therapy11 12 and eventually suffering the consequences of chronic steroid administration.

This small study suggests that treatment with “transplant doses” of cyclophosphamide without stem cell rescue is well tolerated and effective in patients with refractory AIHA. The majority of patients achieved a durable CR, including 5 of 6 with primary AIHA and 2 of 3 who failed splenectomy. Although this approach is associated with prolonged aplasia in patients with severe aplastic anemia,4,5 hematopoietic reconstitution is rapid in patients with autoimmune disorders and normal bone marrow function.7-9 Because autografting is not required, the potential risk of relapse from reinfusing autoreactive effectors is avoided. Thus, further study of this approach as treatment for refractory AIHA is warranted.

Prepublished online as Blood First Edition Paper, April 17, 2002; DOI 10.1182/blood-2002-01-0087.

Supported in part by National Institutes of Health grant CA 70970. R.A.B. is a Clinical Scholar of the Leukemia and Lymphoma Society of America. V.M.M. is a Thomas E. Sanderfur Jr Fellow for Stem Cell Research and an Amgen Clinical Fellow.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Santos
GW
Burke
PJ
Sensenbrenner
LL
Owens
AH
Jr
Rationale for the use of cyclophosphamide as an immunosuppressant for marrow transplants in man.
Proceeding of the International Symposium on Pharmacological Treatment in Organ and Tissue Transplantation.
Bertelli
A
Monaco
AP
1970
24
31
Excerpta Medica Foundation
Amsterdam, The Netherlands
2
Thomas
ED
Storb
R
Fefer
A
et al
Aplastic anaemia treated by marrow transplantation.
Lancet.
1
1972
284
289
3
Jones
RJ
Barber
JP
Vala
MS
et al
Assessment of aldehyde dehydrogenase in viable cells.
Blood.
85
1995
2742
2746
4
Brodsky
RA
Sensenbrenner
LL
Jones
RJ
Complete remission in acquired severe aplastic anemia following high-dose cyclophosphamide.
Blood.
87
1996
491
494
5
Brodsky
RA
Sensenbrenner
LL
Smith
BD
et al
Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia.
Ann Intern Med.
135
2001
477
483
6
Jaime-Perez
JC
Gonzalez-Llano
O
GomezAlmaguer
D
High-dose cyclophosphamide in the treatment of severe aplastic anemia in children [letter].
Am J Hematol.
66
2001
71
7
Brodsky
RA
Petri
M
Smith
BD
et al
Immunoablative high-dose cyclophosphamide without stem cell rescue for refractory severe autoimmune disease.
Ann Intern Med.
129
1998
1031
1035
8
Nousari
HC
Brodsky
RA
Jones
RJ
et al
Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease.
J Am Acad Dermatol.
40
1999
750
754
9
Hayag
MV
Cohen
JA
Kerdel
FA
Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris.
J Am Acad Dermatol.
43
2000
1065
1069
10
Brodsky
RA
Fuller
AK
Ratner
LE
Leffell
MS
Jones
RJ
Elimination of alloantibodies by immunoablative high-dose cyclophosphamide.
Transplantation.
71
2001
482
484
11
Schwartz
RS
Berkman
EM
Silberstein
LE
Autoimmune hemolytic anemias.
Hematology: Basic Principles and Practice.
3rd ed.
Hoffman
RH
Benz
EJ
Jr
Shattil
SJ
et al
2000
611
630
Churchill Livingstone
Philadelphia, PA
12
Petz
LD
Garratty
G
Management of autoimmune hemolytic anemias.
Acquired Immune Hemolytic Anemias.
Petz
LD
Garratty
G
1980
392
440
Churchill Livingstone
New York, NY
13
Ahn
YS
Harrington
WJ
Mylvaganam
R
Ayub
J
Pall
LM
Danazol therapy for autoimmune hemolytic anemia.
Ann Intern Med.
102
1985
298
301
14
Allgood
JW
Chaplin
H
Jr
Idiopathic acquired autoimmune hemolytic anemia: a review of forty-seven cases treated from 1955 through 1965.
Am J Med.
43
1967
254
273
15
Rosse
W
Bussel
J
Ortel
T
Challenges in managing autoimmune disease. American Society of Hematology Education Book.
1997
92
101
16
Akpek
G
McAneny
D
Weintraub
L
Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease.
Am J Hematol.
61
1999
98
102
17
Diehl
LF
Ketchum
LH
Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia.
Semin Oncol.
25
1998
80
97
18
Flores
G
Cunningham-Rundles
C
Newland
AC
Bussel
JB
Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients.
Am J Hematol.
44
1993
237
242

Author notes

Robert A. Brodsky, Division of Hematological Malignancies, Bunting-Blaustein Cancer Research Building, 1650 Orleans St, Rm 242, Baltimore, MD 21231; e-mail: rbrodsky@jhmi.edu.

Sign in via your Institution